NAT2 and injury: Jaramillo-Valverde et al., 2022 [58] studied the possible association with the development of drug-induced liver injury and NAT2 and CYP2E1 polymorphisms in Peruvian patients; those findings showed that patients who had NAT2*4/*5 and had the CYP2E1 c1/c1 genotype had significant protection (OR: 0.16; 95% CI: 0.00–1.25; p = 0.049) against developing drug-induced liver injury compared with the most prevalent combination between the NAT2 and CYP2E1 genotypes (NAT2*5/*5 and CYP2E1 c1/c1).